Moderna Turns First Profit, Boosted by Its COVID-19 Vaccine


Moderna today, saying it's covert 19 vaccine is 6 96% effective in Children ages 12 to 17, the drug maker, announcing the results of its face to trial at the same time, it reported first quarter earnings. It says it's vaccine generated more than $1.5 billion in revenue in its first quarter. This morning's announcement comes ahead of Fizer is expected approval from federal regulators early next week to use its vaccine and adolescents. Currently, covert vaccines are only approved for people 16 and older federal approval of one or more vaccines against the disease could mean many middle and high school students could be vaccinated before school begins in

Coming up next